Company intelligence / Profile preview

Personal Genome Diagnostics

Baltimore, Maryland, United Statespersonalgenome.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

PGDx has FDA-cleared comprehensive genomic profiling (CGP) tests for tissue and plasma biopsies; Elio Tissue Complete provides simultaneous analysis of over 500 genes, and Elio Plasma Resolve received Breakthrough Device Designation. The company has scaled precision diagnostics to enable rapid, in-lab NGS testing for actionable cancer mutations and biomarkers, distributed worldwide

Therapeutic areas: Oncology
Modalities: Diagnostic assay (e.g., NGS-based diagnostic test)DeviceKit
Industry: Molecular Diagnostics

Partnerships

Almac Diagnostic Services (clinical trials and CDx development)Five Prime Therapeutics (companion diagnostic for bemarituzumab)Blueprint (cancer genomics research)

Beyond the preview

Go deeper on Personal Genome Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Personal Genome Diagnostics.

Explore the full profile